Bioequivalence

21
Oct

OGD Announces GDUFA Science and Research Priority Initiatives

Yesterday, the FDA provided the 2027 science and research initiatives which were determined in collaboration with industry and the public, including feedback received during the FY 2026 Generic Drug Science and Research Initiatives Public Workshop. Each year through the GDUFA program, FDA identifies areas of research that address important and challenging scientific issues for “critical […]

Read More
21
Aug

More Product Specific Bioequivalence Recommendations Hit the Press

Today, the FDA published 55 product specific guidances (PSGs) that provide FDA’s current bioequivalence recommendations for generic products. The PSGs can be found here and the current listing represents 24 new and 31 revised PSGs. FDA says that today’s batch of 55 PSGs contain: More than 30 for products with no approved ANDAs including 15 […]

Read More
28
Jul

Newly Revised Product Specific Guidances Issued in an Unusual Posting

Usually, every quarter, the FDA issues a series of new and revised product specific bioequivalence guidances designed to provide the industry with FDA’s current thinking on the appropriate methods to establish bioequivalence of certain products. Today, FDA issued a list (here) composed of only newly revised guidances and all of them are for injectable peptide […]

Read More
17
Jul

Get Your Reading Glasses On – CDER Guidance Plans for 2026 Cite 85 Documents

With four and a half months remaining in fiscal year 2026, the Center for Drug Evaluation and Research (CDER) has published the list of 85 new or revised guidance documents that it plans to release this year! The document (here) categories along with the number of anticipated guidances are as follows: Administrative/Procedural – 8 Artificial […]

Read More
21
May
New list of PSGs blog image

FDA Announces the Publication of New Set of Product Specific Guidances

In this morning’s Federal Register pre-notification page (here), the FDA announced the addition of 23 new Product-Specific Guidances (PSGs) and 48 revised PSG documents. The FDA began publishing PSGs on June 11, 2010 when it announced its first group of PSGs to assist firms in understanding the FDA’s current thinking on the bioequivalence requirements for specific […]

Read More
24
Apr

Day Two Helpful Hints from the Generic Drugs Forum 2026

The second day of the Generic Drugs Forum provided a significant amount of new and rehashed data, including explanations and suggestions regarding certain application submission issues, including but certainly not limited to DMFs, data integrity and the ongoing nitrosamine saga. Here are a few of the helpful hints presented: When providing amendments to DMF, the […]

Read More
26
Feb
98 New and Revised PSGs Issued Today - Lachman Blog

98 New and Revised PSGs Issued Today

Today, the Office of Generic Drugs announced the issuance of 98 Product-Specific Guidances (PSGs). The guidances can be accessed here. In an email announcing the availability of the newly issued guidances, the FDA said: “Today’s batch of 98 PSGs (31 New and 67 Revised) contains: 68 PSGs for products with no approved ANDAs (including 31 complex products) 46 PSGs […]

Read More
04
Feb
It's the end of school year finally!

Q1/Q2 Legislation Finally Becomes Law

On Tuesday, the Association of Accessible Medicines (AAM) heralded the passage of the Q1/Q2 bill as a mechanism to speed certain generic drugs through the FDA approval system by making information on the qualitative and quantitative formulation of certain products available to generic manufacturers seeking approval a generic version of those products. AAM’s  announcement here […]

Read More
15
Dec
Safety Reporting Requirements - Lachman Blog

FDA Issues Two Guidance Documents to Help Sponsors with Safety Reporting Requirements

In an email announcing the two new guidances, the FDA said, “[t]he first guidance titled Investigator Responsibilities — Safety Reporting for Investigational Drugs and Devices is intended for investigators, industry, and institutional review boards (IRBs). This final guidance provides recommendations to help clinical investigators comply with the safety reporting requirements for investigational new drug application […]

Read More
1 2 … 8